Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Topiramate Treatment of Alcohol Use Disorders in African Americans
NCT03018704 · VA Office of Research and Development · PHASE4 · terminated · last registry update 2023-03-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “In ability to recruit” | – | Registry record, VA Office of Research and Development |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CA2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-03-01Also stopped (withdrawn): University of Alabama at Birmingham, [O-15]Water + Acetazolamide (NCT03806751)
- 2024-02-08Phase 3 first posted: Kafrelsheikh University, Valproic acid + Topiramate 50 MG (NCT06248931)
- 2024-02-06Phase 3 first posted: Kafrelsheikh University, Lacosamide 50 MG + Topiramate 50Mg Tab (NCT06243692)
- 2024-01-18Results posted on the registry: Sun Pharmaceutical Industries Limited, Brinzolamide ophthalmic suspension + Azopt® (NCT05022004)
- 2024-01-03Results posted on the registry: CrystalGenomics, Inc., CG100649 + Ketoconazole (NCT01154764)
- 2023-12-12Phase 3 first posted: Johannes Grand, Acetazolamide + Metolazone 2.5 MG (NCT06166654)
- 2023-12-05Also stopped (terminated): Alcon Research, Travoprost 0.004% + Brinzolamide 1.0% + Travoprost 0.004% + Tears Natural (NCT00758342)
- 2023-11-24Phase 3 first posted: Incannex Healthcare Ltd, IHL-42X Low Dose + IHL-42X High Dose (NCT06146101)
- 2023-11-18Results posted on the registry: VA Office of Research and Development, topiramate + placebo (NCT03176953)
- 2023-11-14Results posted on the registry: Virginia Commonwealth University, topiramate (NCT02878798)
- 2023-10-26Also stopped (withdrawn): University of Minnesota, Qsymia and lifestyle management therapy (NCT05834062)
- 2023-08-02Phase 3 first posted: Jadran Galenski laboratorij d.d., Dorzotimol eye drops, 20 mg/mL + 5 mg/mL + Cosopt eye drops, 20 mg/mL + 5 mg/mL (NCT05973318)
- 2023-08-02Phase 3 first posted: Jadran Galenski laboratorij d.d., Dorzol 20 mg/ml + Trusopt 20 mg/ml (NCT05973305)
- 2023-07-27Results posted on the registry: University of Wisconsin, Madison, Acetazolamide (NCT03377049)
- 2023-07-24Phase 3 first posted: Lady Hardinge Medical College, Topiramate (NCT05958160)
- 2023-07-18Results posted on the registry: Mayo Clinic, Phentermine-Topiramate + Liraglutide (NCT03374956)
- 2023-07-11Phase 3 first posted: Tehran University of Medical Sciences, a drug against CA2 (NCT05940220)
- 2023-06-22Results posted on the registry: Mayo Clinic, Phentermine-Topiramate Extended Release + Placebo (NCT04408586)
- 2023-04-27Also stopped (terminated): The University of Texas Health Science Center, Houston, Acetazolamide + Placebo (NCT02466074)
- 2023-03-06Results posted on the registry: Padagis LLC, Brinzolamide 1% ophthalmic suspension + Azopt 1% Ophthalmic Suspension (NCT04024072)
- 2023-03-01Results posted on the registry: The University of Texas Health Science Center, Houston, Acetazolamide + Placebo (NCT02466074)
- 2023-02-28Phase 3 first posted: AbbVie, Atogepant + Placebo for Atogepant (NCT05748483)
- 2023-02-15Results posted on the registry: CrystalGenomics, Inc., CG100649 + Celecoxib (NCT01765296)
- 2023-02-14Also stopped (terminated): Hartford Hospital, Administration of weight loss drug (Metformin or Topiramate) (NCT03603080)
- 2023-02-09Results posted on the registry: CrystalGenomics, Inc., CG100649 + Celecoxib (NCT01341405)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision